This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Van Gaal, L. F Articles by Ballaux, D. Search for Related Content Social Bookmarking                         What's this?

Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid

Department of Diabetology, Metabolism and Nutrition, Antwerp University Hospital, University of Antwerp, Belgium, luc.van.gaal{at}uza.be

Frida Peiffer

Department of Diabetology, Metabolism and Nutrition, Antwerp University Hospital, University of Antwerp, Belgium

Dominique Ballaux

Department of Diabetology, Metabolism and Nutrition, Antwerp University Hospital, University of Antwerp, Belgium

Current treatment guidelines highlight the increased cardiovascular risk associated with type 2 diabetes and identify the need for intensive risk factor management. Dyslipidaemia characterised by elevated serum triglycerides, low levels of high-density lipoprotein cholesterol (HDL-C) and an increase in small, dense low-density lipoprotein cholesterol (LDL-C) particles (the lipid triad), is one of the most important modifiable cardiovascular risk factors in patients with type 2 diabetes. Statins, which are effective in reducing LDL-C, are currently considered the foundation of lipid-lowering treatment in type 2 diabetes, in addition to lifestyle modification. Increasingly, guidelines also identify low HDL-C as an important secondary priority for treatment. Of the available treatment options, both fibrates and nicotinic acid are effective in treating dyslipidaemia associated with type 2 diabetes, although the latter has greater potency in raising HDL-C. Based on its profile of activity, addition of nicotinic acid to primary statin therapy would be a logical strategy in the treatment of diabetic dyslipidaemia. Outcome data from large prospective studies are awaited to confirm the potential morbidity and mortality benefits of this approach.

Key Words: type 2 diabetes • dyslipidaemia • treatment • high-density lipoprotein cholesterol.

References

• Miettinen H., Lehto S., Salomaa V. et al. Impact of diabetes on mortality after first myocardial infarction. Diabetes Care 1998;21:69-75.[Abstract]
• Haffner SM, Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-34.[Abstract/Free Full Text]
• Kannel WG, McGee DL Diabetes and cardiovascular risk factors: the Framingham Study. Circulation 1979;59:8-13.[Abstract/Free Full Text]
• Kannel WB Metabolic risk factors for coronary heart disease in women: perspectives from the Framingham study. Am Heart J 1987; 114:413-29.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Barrett-Conner E., Cohn BA, Wingard DL, Edelstein SL Why is diabetes mellitus a stronger risk factor for fatal ischaemic heart disease in women than men? JAMA 1991;265:627-31.[Abstract/Free Full Text]
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.[Free Full Text]
• De Backer G., Ambrosioni E., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Executive Summary. Eur Heart J 2003;24:1601-10.[Free Full Text]
• International Atherosclerosis Society. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease. Available from www.athero.org. [Accessed 10 July 2005].
• Lee W., Min W-K., Chun S. et al. Low-density lipoprotein subclass and its correlating factors in diabetics. Clin Biochem 2003;36:657-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gardner CD, Fortmann SP, Krauss RM Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276:875-81.[Abstract/Free Full Text]
• Williams PT, Superko HR, Haskell WL et al. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol 2003;23:314-21.[Abstract/Free Full Text]
• American Diabetes Association. Dyslipidaemia management in adults with diabetes. Diabetes Care 2004;27(suppl 1):S68-S71.[CrossRef][Medline] [Order article via Infotrieve]
• Diabetes Atorvastatin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidaemia: the DALI study: a double-blind, randomised, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidaemia. Diabetes Care 2001;24:1335-41.[Abstract/Free Full Text]
• Pontrelli L., Parris W., Adeli K., Cheung RC Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002;51:33442.
• Soedamah-MuthuSS, Colhoun HM, Thomason MJ et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 2003;167:243-55.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pyorala K., Pedersen TR, Kjekshus J., Faedeman O., Olsson A., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.[Abstract]
• Goldberg RB, Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial: the CARE investigators. Circulation 1998;98:2513-19.[Abstract/Free Full Text]
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. A randomised placebo-controlled trial. Lancet 2002;360: 7-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• American Diabetes Association annual meeting 2005 [abstract].
• Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15.[Abstract/Free Full Text]
• Turner RC, Millns H., Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus (UKPDS 23). BMJ 1998;316:823-8.[Abstract/Free Full Text]
• Drexel H., Aczel S., Marte T. et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 2005;28:101-07.[Abstract/Free Full Text]
• Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;34:410-18.
• Rubins HB, Robins SJ, Collins D. et al. Diabetes, plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002;162:2597-604.[Abstract/Free Full Text]
• Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Elkeles RS, Diamond JR, Poulter C. et al. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) study. Diabetes Care 1998;21:641-8.[Abstract]
• Van Gaal LF, Wauters MA, De Leeuw IH The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997;21(suppl 1):S5-S9.[Web of Science]
• Nissen SE, Tuzcu EM, Schoenhagen P. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA 2004;291:1071-80.[Abstract/Free Full Text]
• Cannon CP, Braunwald E., McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.[Abstract/Free Full Text]
• Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002;18:269-76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Shepherd J., Betteridge J., Van Gaal L. on behalf of a European Consensus Panel. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome. A position paper developed by a European Consensus Panel. Curr Med Res Opin 2005;21:665-82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Koskinen P., Manttari M., Manninen V. et al. Coronary heart disease in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820-5.[Abstract]
• Ericsson CG, Hamsten A., Nilsson J., Grip L., de Faire U. Angiographic assessment of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Frick MH, Syvanne M., Nieminen MS et al. Prevention of angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96:2137-43.[Abstract/Free Full Text]
• Fruchart JC, Brewer HB, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and CAD. Am J Cardiol 1998;81:912-17.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Goldberg A., Alagona P. Jr, Capuzzi DM et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100-05.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Guyton JR, Blazing MA, Hagar J. et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000;160:1177-84.[Abstract/Free Full Text]
• Canner PL, Furberg CD, Terrin ML, McGovern ME Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005;95:254-7[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Garg A., Grundy SM Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990;264:723-6.[Abstract/Free Full Text]
• Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycemia control in patients with diabetes and peripheral arterial disease: the ADMIT study, a randomized trial. JAMA 2000;284:1263-70.[Abstract/Free Full Text]
• Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of the Assessment of Diabetes control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 2002;162:1568-76.[Abstract/Free Full Text]
• Knopp RH, Alagona P., Davidson M. et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47:1097-104.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• McGovern ME Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome. Br J Diabetes Vasc Dis 2004;4:78-85.[Abstract/Free Full Text]
• Haffner SM, Alexander CM, Cook TJ et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159:2661-7.[Abstract/Free Full Text]
• Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 6, 344-350 (2005)
DOI: 10.1177/14746514050050060901


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. J Krentz Effective management of type 2 diabetes and metabolic syndrome: beyond glucose control The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 303 - 304. [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Van Gaal, L. F Articles by Ballaux, D. Search for Related Content Social Bookmarking                         What's this?